Skip to main content
OpenTrials
Completed

NCT Number: NCT05645354

SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups

The purpose of this study is to test the feasibility and acceptability of Smokefree Sexual and Gender Minority (SGM), an SGM-tailored version of the SmokefreeTXT text messaging program

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-identify as an LGBTQ+ individual
  • Currently live in the United States
  • Have smoked at least 100 cigarettes in their lifetime, smoke every day, and smoke greater than or equal to 5 cigarettes a day
  • Are willing to quit smoking in the next 15 days
  • Have a cell phone number with an unlimited short message service (SMS) plan
  • Have a positive cotinine saliva test to indicate their smoking status

Exclusion criteria

  • Have a prepaid cell phone plan (pay-as-you-go plan)
  • Have a cell phone number that does not work and/or is registered to someone else
  • Have inadequate equipment/devices (i.e., webcam, speakers, mic) for participating in telehealth sessions via Microsoft Teams, Webex, or Zoom AND cannot meet in-person
  • Pregnant or breastfeeding persons (nicotine patches are not generally recommended to this groups since nicotine can affect fetal and neonatal brain development)
  • Contraindication for nicotine patches. Absolute contraindications include: severe eczema or serious skin conditions, allergy to nicotine patches, pregnancy, breastfeeding, heart attack in the past 2 months, ongoing angina, peptic ulcer disease, arrhythmia, or uncontrolled blood pressure. Potential contraindications include: stroke in the past 6 months, insulin therapy, and a current diagnosis of liver, kidney, or heart disease. Study participants reporting a potential contraindication will require approval from their primary care provider and/or other treating physician (e.g., psychiatrist) to use nicotine patches. If the request is denied or not returned in 2 weeks, potential study participants will be excluded from the study.
  • Current use of tobacco cessation medications
  • Enrollment in another smoking cessation study
  • Non-English speakers

Treatment and study plan

SmokefreeSGM

Behavioral

Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.

SmokefreeTXT

Behavioral

Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population

Primary outcomes

  1. Feasibility as Assessed by Number of Participants Recruited for the Study

    Time frame: Baseline

  2. Feasibility as Assessed by Number of Participants That Completed Month 1 Visit

    Time frame: end of month 1

  3. Feasibility as Assessed by Number of Participants That Completed Month 3 Visit

    Time frame: end of month 3

  4. Feasibility as Assessed by Number of Participants That Completed Month 6 Visit

    Time frame: end of month 6

  5. Acceptability as Assessed by Number of Participants Who Completed Qualitative Interviews

    Time frame: 6 months follow up

Secondary outcomes

  1. Number of Participants That Quit Smoking

    Time frame: 1 month follow up

  2. Number of Participants That Quit Smoking

    Time frame: 3 month follow up

  3. Number of Participants That Quit Smoking

    Time frame: 6 month follow up

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 9, 2022
Registry last updated
Aug 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.